Vir Biotechnology Inc (VIR)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 222,947 | 257,948 | 310,810 | 174,046 | 254,844 | 452,100 | 666,949 | 824,913 | 848,631 | 963,735 | 1,505,180 | 812,355 | 347,815 | 714,521 | 741,951 | 521,396 | 436,575 | 462,521 | 371,781 | 168,418 |
| Short-term investments | US$ in thousands | 682,401 | 746,124 | 854,201 | 989,052 | 1,280,830 | 1,244,450 | 1,180,480 | 1,425,160 | 1,553,410 | 1,382,750 | 690,520 | 447,719 | 360,330 | 224,929 | 84,107 | 211,636 | 300,286 | 364,074 | 180,599 | 187,193 |
| Total current liabilities | US$ in thousands | 119,662 | 117,161 | 96,412 | 94,068 | 175,407 | 165,050 | 225,623 | 485,288 | 511,029 | 308,203 | 477,868 | 702,361 | 341,242 | 233,724 | 146,024 | 361,099 | 99,064 | 76,998 | 54,940 | 56,396 |
| Cash ratio | 7.57 | 8.57 | 12.08 | 12.36 | 8.75 | 10.28 | 8.19 | 4.64 | 4.70 | 7.61 | 4.59 | 1.79 | 2.08 | 4.02 | 5.66 | 2.03 | 7.44 | 10.74 | 10.05 | 6.31 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($222,947K
+ $682,401K)
÷ $119,662K
= 7.57
The cash ratio of Vir Biotechnology Inc has shown fluctuating values over the periods reported. The cash ratio measures the company's ability to cover its short-term obligations with its cash and cash equivalents.
From March 31, 2020, to December 31, 2024, the cash ratio ranged from a low of 1.79 to a high of 12.36. Generally, a higher cash ratio indicates a stronger liquidity position as the company has more cash on hand to cover its short-term liabilities.
The company experienced a significant decrease in cash ratio from March 31, 2021, to September 30, 2022, suggesting a potential strain on its liquidity position during this period. However, from September 30, 2022, to March 31, 2024, there was an upward trend in the cash ratio, indicating an improvement in the company's ability to meet short-term obligations with its available cash resources.
Overall, the cash ratio trend of Vir Biotechnology Inc indicates fluctuations in its liquidity position over the reported periods, with some periods showing stronger liquidity than others. Investors and stakeholders may need to monitor these fluctuations to assess the company's ability to meet its short-term financial commitments.
Peer comparison
Dec 31, 2024